Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a VR headset calm chemo anxiety? new study tests hypnosis in prostate cancer patients

NCT ID NCT04533958

Symptom relief Sponsor: Saint-Gregoire Private Hospital Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether using virtual reality hypnosis before chemotherapy infusions could lower anxiety in men with metastatic prostate cancer. Fifty-three patients were randomly assigned to either receive the VR hypnosis session or standard care before each docetaxel infusion. Researchers measured anxiety levels and nausea to see if the VR approach made treatment less stressful.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HYPNO VR® device (virtual reality hypnosis software with headset and headphones)
What this could lead to
If it works, this could offer a drug-free way to reduce anxiety and nausea during chemotherapy for men with metastatic prostate cancer.
What could go wrong
This is a small, single-center study with only 53 participants, so results may not apply to everyone. The effect on anxiety may be modest or no different from standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

53 people

The number who actually took part.

Started

Sep 2020

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Man aged ≥ 18 years * Histologically proven metastatic prostate adenocarcinoma, * Patient undergoing chemotherapy according to the following conventional scheme: 12 courses of Docetaxel every two weeks * Patient who signed their informed consent * Patient benefiting from social security coverage * Patient treated and followed in the center for the duration of the study (6 months maximum). Exclusion Criteria: * Patient participating in another clinical trial on an experimental molecule * Patient who received previous chemotherapy * Patient unable to submit to protocol monitoring for psychological, social, family or geographic reasons * Patient deprived of their liberty or under guardianship * Patient with underlying or concomitant pathology incompatible with inclusion in the trial, whether psychiatric or somatic

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic prostate cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anxiety disorder metastatic prostate carcinoma neoplasm prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic prostate cancer

Contacts and locations

Locations

  • CHP Saint-Grégoire

    Saint-Grégoire, 35760, France

  • Clinique Pasteur-Lanroze

    Brest, 29200, France

  • Clinique de la Côte d'Emeraude

    St-Malo, 35400, France

  • Hospital Lusiadas Amadora

    Amadora, 2724-002, Portugal

  • Hospital Lusiadas Lisboa

    Lisbon, 1500-458, Portugal

  • Hospital Lusiadas Porto

    Porto, 4050-115, Portugal

More trials for these conditions

Other studies related to the condition(s) this trial covers.